According to EULAR recommendations, it is recommended that RA patients in need of bDMARDs (especially TNF inhibitors) be treated in combination with sDMARDs because of the superior efficacy compared with monotherapy using either sDMARDs or bDMARDs [20]. This evidence concerns the gene TNF and rheumatoid arthritis.